Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively. Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008). Materials and Methods: Three randomized phase III trials representing 1502 patients were identified. Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model. Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials / Marchetti, C; DE FELICE, Francesca; Palaia, Innocenza; Musella, Angela; DI DONATO, Violante; Gasparri, Marialuisa; Musio, D; Muzii, Ludovico; Tombolini, Vincenzo; BENEDETTI PANICI, Pierluigi. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7:11(2016), pp. 13221-13227. [10.18632/oncotarget.6507]

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials

Marchetti, C
Primo
;
DE FELICE, FRANCESCA
Secondo
;
PALAIA, INNOCENZA;MUSELLA, ANGELA;DI DONATO, VIOLANTE;GASPARRI, MARIALUISA;MUZII, LUDOVICO;TOMBOLINI, Vincenzo
Penultimo
;
BENEDETTI PANICI, PIERLUIGI
Ultimo
2016

Abstract

Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively. Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008). Materials and Methods: Three randomized phase III trials representing 1502 patients were identified. Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model. Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.
2016
bevacizumab; ovarian cancer; recurrent; survival; toxicity
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials / Marchetti, C; DE FELICE, Francesca; Palaia, Innocenza; Musella, Angela; DI DONATO, Violante; Gasparri, Marialuisa; Musio, D; Muzii, Ludovico; Tombolini, Vincenzo; BENEDETTI PANICI, Pierluigi. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7:11(2016), pp. 13221-13227. [10.18632/oncotarget.6507]
File allegati a questo prodotto
File Dimensione Formato  
Marchetti_Efficacy and toxicity _2016.pdf

accesso aperto

Note: https://www.oncotarget.com/article/6507/text/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.16 MB
Formato Adobe PDF
2.16 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/874860
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 19
social impact